A therapeutic protein called PAK has been reported to reduce the progression of triple-negative breast cancer in cells and in animal models via degradation of SREBP1 mRNA and fatty acid biosynthesis [140]. This evidence concerns the gene SREBF1 and triple-negative breast carcinoma.